FDA Eliminates Risk Plan For Avandia Diabetes Drugs; Risks Don’t Outweigh Benefits

(December 17, 2015, 2:14 PM EST) -- SILVER SPRING, Md. — The Food and Drug Administration on Dec. 16 said it is eliminating the risk evaluation and mitigation strategy (REMS) for type 2 diabetes medicines that contain rosiglitazone,...
To view the full article, register now.